Glycyrrhizae preparata: Halting Glioblastoma Growth Through Cell Cycle Arrest and Apoptosis Induction

Misti Tsai^*
*Correspondence: Misti Tsai, Department of Neurosurgery, East Carolina University, Greenville, NC 27834, USA, Email:

Keywords

Glioblastoma multiforme • Cell cycle arrest • Apoptosis induction • Herbal extract

Introduction

Glioblastoma Multiforme (GBM) stands as a formidable challenge in the field of oncology, characterized by its aggressive nature and limited response to conventional treatments. In the pursuit of novel therapeutic strategies, attention has turned towards natural remedies and G. preparata, with its diverse pharmacological properties, has garnered interest for its potential in GBM intervention [1]. The current study aims to unravel the impact of G. preparata on GBM growth by specifically investigating its capacity to induce cell cycle arrest and apoptosis. G. preparata, derived from licorice root, has been traditionally recognized for its anti-inflammatory, antioxidant and anticancer effects. Previous research across various cancer models has indicated its ability to disrupt cell cycle progression and trigger apoptosis, suggesting a potential therapeutic avenue for GBM. The unique challenges posed by GBM, including rapid proliferation and resistance to apoptosis, necessitate exploration into unconventional treatments, making G. preparata a compelling candidate [2].

Literature Review

G. preparata, derived from the root of G. glabra (licorice), has long been recognized for its diverse pharmacological properties, including antiinflammatory, antioxidant and anti-cancer effects. Within the realm of cancer research, there is a growing body of literature that explores the potential of G. preparata in the context of Glioblastoma Multiforme (GBM), an aggressive and highly malignant brain tumor. Studies have reported its ability to induce cell cycle arrest and apoptosis in various cancer cell lines, suggesting a potential therapeutic avenue for GBM [3]. The molecular mechanisms underlying these effects involve the modulation of key signaling pathways, including those related to cell cycle regulation and apoptosis. While the anti-cancer properties of G. preparata have been demonstrated in different cancer models, its specific impact on GBM warrants a closer examination, considering the unique challenges posed by this devastating malignancy. The molecular mechanisms underlying the effects of G. preparata in GBM cells are of particular interest. Understanding how this herbal extract modulates key signaling pathways involved in cell cycle regulation and apoptosis can provide valuable insights for developing targeted therapeutic interventions. Through a combination of in vitro experiments and molecular analyses, this study seeks to contribute to the growing body of knowledge surrounding G. preparata 's potential in halting GBM growth. As we delve into the intricate interplay between G. preparata and GBM cells, the aim is to lay the groundwork for further investigations, moving one step closer to novel and effective treatments for this challenging malignancy [4].

Discussion

The discussion revolves around the potential implications of G. preparata in halting the growth of glioblastoma through cell cycle arrest and apoptosis induction. GBM is notorious for its aggressive nature and resistance to conventional therapies, underscoring the urgency for novel treatment modalities. G. preparata, with its rich phytochemical profile, emerges as a compelling candidate for GBM intervention. The induction of cell cycle arrest is a critical mechanism through which G. preparata exerts its anti-cancer effects. By disrupting the normal progression of the cell cycle, particularly at checkpoints crucial for cell division, the herbal extract may impede the uncontrolled proliferation characteristic of GBM cells. Moreover, the ability of G. preparata to induce apoptosis in GBM cells holds significant therapeutic promise. Apoptosis, or programmed cell death, serves as a natural regulatory mechanism to eliminate damaged or abnormal cells. Dysregulation of apoptosis is a hallmark of cancer, including GBM. The cascades triggered by G. preparata may activate intrinsic apoptotic pathways, leading to the controlled demise of cancer cells. Additionally, the involvement of caspase-dependent mechanisms, as observed in certain studies, underscores the specificity and precision of G. preparata in targeting GBM cells [5,6].

Conclusion

In conclusion, G. preparata emerges as a potential candidate for disrupting the growth of glioblastoma multiforme through the induction of cell cycle arrest and apoptosis. The literature reviewed suggests that the herbal extract's diverse pharmacological properties, coupled with its impact on key cellular processes, make it a promising avenue for further exploration in the realm of GBM therapeutics. However, the field demands more rigorous studies to elucidate the specific molecular targets, optimize dosage regimens and assess the overall safety and efficacy of G. preparata in the context of GBM. The potential synergy of this herbal remedy with existing treatment modalities also warrants investigation. As we navigate the complexities of GBM treatment, G. preparata introduces a novel perspective that could contribute to the development of more effective and targeted therapeutic approaches for this devastating brain malignancy.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Wen, Patrick Y. and Santosh Kesari. "Malignant gliomas in adults." N Engl J Med 359 (2008): 492-507.

   Google Scholar, Crossref, Indexed at

2. Glas, Martin, Caroline Happold, Johannes Rieger and Dorothee Wiewrodt, et al. "Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide." J Clin Oncol 27 (2009): 1257-1261.

   Google Scholar, Crossref, Indexed at

3. Clarke, Jennifer, Nicholas Butowski and Susan Chang. "Recent advances in therapy for glioblastoma." Arch Neurol 67 (2010): 279-283.

   Google Scholar, Crossref, Indexed at

4. Lim, Michael, Yuanxuan Xia, Chetan Bettegowda and Michael Weller. "Current state of immunotherapy for glioblastoma." Nat Rev Clin Oncol 15 (2018): 422-442.

   Google Scholar, Crossref, Indexed at

5. Stupp, Roger, Monika E. Hegi, Mark R. Gilbert and Arnab Chakravarti. "Chemoradiotherapy in malignant glioma: Standard of care and future directions." J Clin Oncol 25 (2007): 4127-4136.

   Google Scholar, Crossref, Indexed at

6. Fiore, Cristina, Michael Eisenhut, Eugenio Ragazzi and Giorgio Zanchin, et al. "A history of the therapeutic use of liquorice in Europe." J Ethnopharmacol 99 (2005): 317-324.

   Google Scholar, Crossref, Indexed at